Skip to main content

Table 2 Relationship of baseline (start of infusion) values to 28-day mortality in PROWESS placebo patients

From: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

Baseline measure

Cut-offa

Number of patients at increased risk using cut-off (n [%])

Odds ratio (95% CI)

AUCb

Protein C (%)

<40

243 (31.4%)

2.12 (1.55–2.89)

58.9%

Protein S (%)

<46

239 (31.5%)

1.91 (1.38–2.64)

57.7%

Antithrombin III (%)

<53

240 (31.4%)

2.32 (1.70–3.18)

60.1%

interleukin-6 (pg/ml)

≥704.6

252 (31.2%)

2.21 (1.63–2.99)

59.7%

Prothrombin time (seconds)

≥18.4

240 (31.5%)

1.89 (1.38–2.58)

57.4%

D-dimer (μg/ml)

≥4.45

241 (31.8%)

1.51 (1.11–2.05)

55.1%

Cardiovascular SOFA

≥4

259 (30.8%)

1.63 (1.21–2.18)

56.0%

Respiratory SOFA

≥4

257 (31.2%)

1.76 (1.27–2.44)

55.5%

Renal SOFA

≥1

258 (30.8%)

2.14 (1.55–2.95)

58.6%

Hematologic SOFA

≥2

259 (30.8%)

1.69 (1.20–2.38)

54.6%

Hepatic SOFA

≥2

239 (31.3%)

1.31 (0.89–1.93)

52.1%

  1. aCut-off based on maximum sensitivity and specificity when both were ≥ 40% for predicting 28-day mortality. Using a cut-off for each measure allowed comparison of odds ratios and treatment interactions on a consistent binary scale across variables. bArea under the receiver operating characteristic curve (AUC) based on 28-day mortality outcome in logistic regression models with the cut-off as the univariate independent variable; this is a combined measure of sensitivity and specificity. CI, confidence interal; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; SOFA, Sequential Organ Failure Assessment.
Back to article page

Critical Care

ISSN: 1364-8535